Many of these inhibitors are unable to cross it, and those that do often exhibit high liver toxicity deemed unrelated to RIPK1 inhibition, making them unsuitable for the treatment of neurodegenerative diseases, where long-term chronic treatment is required (Grievink et al., 2020). The gene discussed is RIPK1; the disease is neurodegenerative disease.